Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eisai Co., Ltd.
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants with histological diagnosis of B-cell non-Hodgkin's lymphoma
Participant who has measurable disease
Participant who had previous therapy with systemic chemotherapy and/or antibody therapy
Participant who had progressive disease (PD) or did not have a response (complete response \[CR\] or partial response \[PR\]) in previous systemic therapy, or relapsed or progressed after previous systemic therapy
Participant with Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
Participant with life expectancy of ≥3 months from starting study drug administration
Participant with adequate renal, bone marrow, and liver function
Participant with left ventricular ejection fraction (LVEF) \> 50%
Male and female participant ≥20 years of age at the time of informed consent
Participant who has provided written consent to participate in the study
You may not be if
Participant with prior exposure to EZH2 inhibitor
Participant with a history or a presence of central nerves invasion
Participant with allogeneic stem cell transplantation
Participant with medical need for the continued use of potent or moderate inhibitors of CYP3A or P-gp, or potent or moderate inducer of CYP3A (including St. John's wort).
Participant with significant cardiovascular impairment
Participant with prolongation of corrected QT interval using Fridericia's formula (QTcF) to \> 480 milliseconds (msec)
Participant with venous thrombosis or pulmonary embolism within the last 3 months before starting study drug
Participant with complications of hepatic cirrhosis, interstitial pneumonia, or pulmonary fibrosis
Participant with active infection requiring systemic therapy
Women of childbearing potential or man of impregnate potential who don't agree to use a medically effective method for contraception for periods from before informed consent to during the clinical study and 30 days later from last administration of study drug
Woman who are pregnant or breastfeeding
Participant who were deemed as inappropriate to participate in the study by the investigator or sub-investigator
Clareo Health | A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
